861532-85-6

Basic information

• Product Name: 3,5-bis-methoxycarbonyloxy-benzoyl chloride
• Synonyms: 3,5-bis-methoxycarbonyloxy-benzoyl chloride
• CAS NO: 861532-85-6
• Molecular Weight: 288.641
• Mol File: 861532-85-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,5-bis-methoxycarbonyloxy-benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-bis-methoxycarbonyloxy-benzoyl chloride(861532-85-6)
• EPA Substance Registry System: 3,5-bis-methoxycarbonyloxy-benzoyl chloride(861532-85-6)

Safety Data

• Hazardous Substances Data: 861532-85-6(Hazardous Substances Data)

Upstream product

• 99-10-5 3,5-Dihydroxybenzoic acid 
• 222320-79-8 3,5-bis-methoxycarbonyloxy-benzoic acid 

Downstream Products

• 856077-23-1 3,5-bis-methoxycarbonyloxy-benzaldehyde 
• 38009-30-2 3,5-dihydroxy-benzophenone 
• 222320-81-2 (2R,3R)-2,3-Bis-(3,5-bis-methoxycarbonyloxy-benzoyloxy)-succinic acid 
• 26153-38-8 3,5-dihydroxybenzaldehyde 

Relevant articles and documents

Structure-activity relationships: Analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication

The dicaffeoylquinic acids (DCQAs) and dicaffeoyltartaric acids (DCTAs) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase. They also inhibit HIV-1 replication at nontoxic concentrations. Since integrase is an excellent target for anti-HIV therapy, structure-activity relationships were employed to synthesize compounds with: (1) improved potency against HIV-1 integrase, (2) improved anti-HIV effect in tissue culture, and (3) increased selectivity as indicated by low cellular toxicity. Thirty-four analogues of the DCTAs and DCQAs were synthesized and tested for cell toxicity, anti-HIV activity, and inhibition of HIV-1 integrase. Seventeen of the 34 analogues had potent activity against HIV-1 integrase ranging from 0.07 to > 10 μM. Seventeen analogues that were synthesized or purchased had no inhibitory activity against integrase at concentrations of 25 μM. Of the biologically active analogues, 7 of the 17 inhibited HIV replication at nontoxic concentrations. The most potent compounds were D-chicoric acid, meso-chicoric acid, bis(3,4- dihydroxydihydrocinnamoyl)-L-tartaric acid, digalloyl-L-tartaric acid, bis(3,4-dihydroxybenzoyl)-L-tartaric acid, dicaffeoylglyceric acid, and bis(3,4-dihydroxyphenylacetyl)-L-tartaric acid. Anti-HIV activity of the active compounds in tissue culture ranged from 35 to 0.66 μM. Structure- activity relationships demonstrated that biscatechol moieties were absolutely required for inhibition of integrase, while at least one free carboxyl group was required for anti-HIV activity. These data demonstrate that analogues of the DCTAs and the DCQAs can be synthesized which have improved activity against HIV integrase.